EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.64
0.00 (0.00%)
As of 12:49PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close9.64
Open9.86
Bid9.67 x 800
Ask9.68 x 900
Day's Range9.54 - 9.86
52 Week Range4.55 - 15.82
Volume96,533
Avg. Volume367,253
Market Cap241.544M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-2.83
Earnings DateAug 06, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick
    Zacks

    Why Eiger BioPharmaceuticals (EIGR) Stock Might be a Great Pick

    Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Hedge Funds Can’t Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR)
    Insider Monkey

    Hedge Funds Can’t Buy Enough Of Eiger BioPharmaceuticals, Inc. (EIGR)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
    PR Newswire

    Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020

    Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eiger is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

  • Eiger to Present at Jefferies Virtual Healthcare Conference 2020
    PR Newswire

    Eiger to Present at Jefferies Virtual Healthcare Conference 2020

    Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, 2020 from 9:30-9:55 PM ET.

  • The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
    Benzinga

    The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * ChemoCentryx Inc (NASDAQ: CCXI) * Evoke Pharma Inc (NASDAQ: EVOK) * I-Mab ADR (NASDAQ: IMAB) * Imara Inc (NASDAQ: IMRA) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Neurocrine Biosciences, Inc. (NASDAQ: NBIX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * Translate Bio Inc (NASDAQ: TBIO) * Twist Bioscience Corp (NASDAQ: TWST) * United Therapeutics Corporation (NASDAQ: UTHR) * VBI Vaccines Inc (NASDAQ: VBIV) * Vermillion, Inc. (NASDAQ: VRML) * Zai Lab Ltd (NASDAQ: ZLAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 19) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1)Stocks In Focus Myriad Announces FDA Approval For Companion Diagnostic Test For Prostate Cancer Myriad Genetics, Inc. (NASDAQ: MYGN) said the FDA approved the BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza.Lynparza is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca plc (NYSE: AZN) and Merck & Co., Inc. (NYSE: MRK).In pre-market trading Wednesday, Myriad shares were advancing 8.21% to $15.68.Aldeyra To Advance Two Pipeline Assets Into Clinical Trials For COVID-19 Treatment Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibitor in development for COVID-19 and other inflammatory diseases.Aldeyra announced that ADX-1612 has demonstrated nanomolar potency similar to or greater than that of remdesivir in an in vitro model. Complementary to the nucleic acid inhibition mechanism of action of remdesivir and related antiviral compounds, ADX-1612 potentially leads to the inhibition of proteins associated with viral replication and infection, and thereby may enhance the activity of other antiviral drugs for the treatment of COVID-19. Pending FDA feedback, the company expects to file an IND the third quarter of 2020.The company said ADX-629 has completed pre-IND discussions with the Pulmonary Division of the FDA, and an IND application is expected to be submitted in June 2020.In pre-market trading, shares were up 23.70% to $4.75.Eiger's NDA For Progeria Drug Accepted For Accelerated Review Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) said the FDA accepted its NDA for an accelerated review of Zokinvy for treatment of Progeria and Progeroid Laminopathies. The PDUFA action date has been fixed for Nov. 20. The company noted that the FDA is not currently planning to hold an advisory committee meeting to discuss this application.View more earnings on IBBRelated Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyBio-Techne Announces Pact to Develop and Scale Up Serology Test Kits For Coronavirus BIO-TECHNE Corp (NASDAQ: TECH) and Kantaro Biosciences, the commercial affiliate of the Mount Sinai Health System in New York, announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test.Bio-Techne said it has partnered with Kantaro to develop a test kit based on the Mount Sinai test and to scale up, manufacture, sell and distribute these kits. Initial kit production capacity is expected to enable laboratories to conduct in excess of 10 million tests monthly in July, scaling to higher capacity in subsequent months..Offerings Ocular Therapeutix Inc (NASDAQ: OCUL) said it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by the company. The company also said the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.The stock fell 4.65% to $6.15 in after-hours trading.Medigus Ltd. (NASDAQ: MDGS) said it has priced its underwritten public offering of 3.33 million ADSs at a price of $1.50 per ADS. Each pre-funded warrant that allows purchase of one ADS is priced at $1.499 per pre-funded warrant. The company noted that the pre-funded warrants are exercisable at any time after the date of issuance upon payment of the exercise price of $0.001 per ADS.The stock slipped 10.24% to $2.63 in after-hours trading.VolitionRX Ltd (NYSE: VNRX) said it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares are being offered by the company.In after-hours trading, the stock fell 7.30% to $2.92.On The Radar Earnings Mediwound Ltd (NASDAQ: MDWD) (before the market open) China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close)See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering * The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows * The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
    PR Newswire

    Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

    Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for accelerated review of Zokinvy™ (lonafarnib) for treatment of Progeria and Progeroid Laminopathies. The FDA granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of November 20, 2020. The FDA is not currently planning to hold an advisory committee meeting to discuss this application. Zokinvy for treatment of Progeria and Progeroid Laminopathies has been granted Rare Pediatric Disease Designation.

  • Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?
    Zacks

    Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?

    Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
    PR Newswire

    Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

    Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in a Phase 2 study of peginterferon lambda (Lambda) in outpatients with mild COVID-19 at the Stanford University School of Medicine.

  • Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
    American City Business Journals

    Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays

    In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.

  • Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
    PR Newswire

    Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

    Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today provided an update on the impact of the rapidly progressing global COVID-19 (SARS-CoV-2) pandemic. Eiger has put into place remote operations and new policies to maintain the safety and well-being of our employees, while working to maintain business continuity as this unprecedented global situation continues to evolve. The company has taken appropriate steps to ensure the safety of patients and the integrity of the HDV Phase 3 D-LIVR trial. We have also begun supporting multiple Investigator-Sponsored Studies of Peginterferon Lambda in COVID-19.

  • Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
    PR Newswire

    Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for lonafarnib for the treatment of Progeria and Progeroid Laminopathies. The FDA previously granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation to lonafarnib, which enables eligibility for Priority Review, if relevant criteria are met. Eiger expects to hear from FDA regarding submission acceptance and Priority Review within 60 days.

  • Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares
    Simply Wall St.

    Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares

    Potential Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shareholders may wish to note that the Founder, Jeffrey Glenn...

  • Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
    PR Newswire

    Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the fourth quarter and full year 2019 and provided a business update.

  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Jan. 17

    Insiders invest in JPMorgan, Simply Good Foods, Eiger BioPharmaceuticals and Geron Continue reading...

  • Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares
    Simply Wall St.

    Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares

    Whilst it may not be a huge deal, we thought it was good to see that the Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR...

  • Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
    PR Newswire

    Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

    Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Eldon Mayer as Executive Vice President and Chief Commercial Officer. Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience in large and specialty pharma across multiple therapeutic areas, including both orphan and larger markets, with multiple successful exits by acquisition.

  • Eiger Updates on 2019 Progress and 2020 Milestones Expected
    PR Newswire

    Eiger Updates on 2019 Progress and 2020 Milestones Expected

    Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today updated on progress across its product pipeline, including clinical and regulatory program planned milestones, and commercial preparation.

  • Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
    PR Newswire

    Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has initiated submission of a New Drug Application (NDA) for Lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies to the U.S. Food & Drug Administration (FDA) under the Rolling Review Process. Lonafarnib, an oral farnesyltransferase inhibitor (FTI), has demonstrated extended survival in children and young adults with Progeria, an ultra-rare and fatal disease that causes premature aging in children. Without treatment, children with Progeria die of heart disease at an average age of 14.5 years.

  • Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]

  • Eiger to Present at Jefferies 2019 London Healthcare Conference
    PR Newswire

    Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November 20, 2019 from 4:00-4:35 PM GMT in London. Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist. The company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.

  • Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
    PR Newswire

    Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    - 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve > 2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , ...

  • Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?
    Insider Monkey

    Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR). Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has seen […]

  • Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
    PR Newswire

    Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    - Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies - Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD - First-Ever Phase 3 HDV International D-LIVR Study Enrolling ...

  • Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
    PR Newswire

    Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019

    - >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve >2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. ...

  • Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?
    Simply Wall St.

    Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

    If you want to know who really controls Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), then you'll have to look at the...